{"id":724,"date":"2023-09-27T18:21:07","date_gmt":"2023-09-27T18:21:07","guid":{"rendered":"https:\/\/onltherapeutics.com\/test\/?page_id=724"},"modified":"2026-01-05T19:31:08","modified_gmt":"2026-01-05T19:31:08","slug":"investors","status":"publish","type":"page","link":"https:\/\/onltherapeutics.com\/test\/investors\/","title":{"rendered":"Investors"},"content":{"rendered":"\n
<\/div>\n\n\n\n

About<\/a><\/p>\n\n\n\n

Investors<\/h2>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

ONL Therapeutics is a privately held biotech company delivering on commitments to its investors to accelerate clinical development of first-in-class therapeutics<\/h3>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

In September 2024, the company closed on a $65 million oversubscribed Series D financing round. Johnson & Johnson Innovation \u2013 JJDC, Inc. led the round that was backed by a consortium of investors that included Bios Partners, Novartis Venture Fund, Visionary Ventures, and ExSight Ventures, amongst others. Proceeds from the Series D will advance the development of xelafaslatide (formerly ONL1204) into a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).<\/p>\n\n\n\n

In August 2023, the company closed on a $15 million Series C Preferred Stock financing round, primarily to support the advancement of its lead compound xelafaslatide into a Phase 2 clinical trial in patients with macula-off rhegmatogenous retinal detachment (RRD). The financing was led by Bios Partners and included new investors Visionary Ventures, Alpine Visionary Ventures and Mayewell Capital, as well as existing investors Johnson & Johnson Innovation \u2013 JJDC, Inc., Kaitai Capital, PSQ Capital, Michigan Capital Network Venture Fund III, ExSight Ventures, the University of Michigan\u2019s Michigan Investment in New Technology Startups (MINTS) program, Western Michigan University\u2019s Biosciences Research & Commercialization Center, and the Capital Community Angels.<\/p>\n\n\n\n

In December 2020, the company closed a $46.8 million Series B round, with Bios Partners leading, joined by fellow new investors Johnson & Johnson Innovation \u2013 JJDC, Inc., Kaitai Capital, InFocus Capital Partners, ExSight Ventures, and Michigan Capital Network Venture Fund III. Proceeds from the Series B financing enabled ONL to complete a Phase I clinical study of xelafaslatide in retinal detachment and advance xelafaslatide in two chronic indications, glaucoma and geographic atrophy associated with dry age-related macular degeneration.<\/p>\n\n\n\n

In prior financing, the company completed a $4.25 million Series A financing round that involved both existing and new investors including Novartis, the University of Michigan\u2019s Michigan Investment in New Technology Startups (MINTS) program, Capital Community Angels, Invest Michigan, Biosciences Research & Commercialization Center and Hestia Investments.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/a><\/figure>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

About Investors ONL Therapeutics is a privately held biotech company delivering on commitments to its investors to accelerate clinical development of first-in-class therapeutics In September 2024, the company closed on a $65 million oversubscribed Series D financing round. Johnson & Johnson Innovation \u2013 JJDC, Inc. led the round that was backed by a consortium of […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"blank","meta":{"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-724","page","type-page","status-publish","hentry"],"featured_image_urls_v2":{"full":"","thumbnail":"","medium":"","medium_large":"","large":"","1536x1536":"","2048x2048":"","gform-image-choice-sm":"","gform-image-choice-md":"","gform-image-choice-lg":""},"post_excerpt_stackable_v2":"

About Investors ONL Therapeutics is a privately held biotech company delivering on commitments to its investors to accelerate clinical development of first-in-class therapeutics In September 2024, the company closed on a $65 million oversubscribed Series D financing round. Johnson & Johnson Innovation \u2013 JJDC, Inc. led the round that was backed by a consortium of investors that included Bios Partners, Novartis Venture Fund, Visionary Ventures, and ExSight Ventures, amongst others. Proceeds from the Series D will advance the development of xelafaslatide (formerly ONL1204) into a Phase 2 global study for the treatment of geographic atrophy (GA) associated with dry age-related…<\/p>\n","category_list_v2":"","author_info_v2":{"name":"theo@myriadweb.com","url":"https:\/\/onltherapeutics.com\/test\/author\/theomyriadweb-com\/"},"comments_num_v2":"0 comments","_links":{"self":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/comments?post=724"}],"version-history":[{"count":26,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/724\/revisions"}],"predecessor-version":[{"id":2661,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/724\/revisions\/2661"}],"wp:attachment":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/media?parent=724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}